Richard Turner Consultant Dermatologist

Similar documents
Skin lesions The Good and the Bad. Dr Virginia Hubbard Ipswich Hospital NHS Trust Barts and the London School of Medicine and Dentistry

Clinical characteristics

I have a skin lump doc! What s next? 12 th August 2017 Dr. Sue-Ann Ho Ju Ee

Diagnosis and Management of Actinic Keratosis (AKs)

Know who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated

Know who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated

Common Benign Lesions and Skin Cancers. 22nd May 2015 Dr Mark Foley

Glenn D. Goldman, MD. University of Vermont Medical Center. University of Vermont College of Medicine

Lumps and Bumps: An Organized Approach to Diagnosis and Management. Disclosure. Introduction. References. Structure of Skin.

Nonmelanoma skin cancers

Living Beyond Cancer Skin Cancer Detection and Prevention

Opinion 26 June 2013

AWMSG SECRETARIAT ASSESSMENT REPORT. Ingenol mebutate (Picato ) 150 micrograms/g gel and 500 micrograms/g gel. Reference number: 1392 FULL SUBMISSION

Premalignant skin tumours

Actinic Keratoses and Bowen s disease

30 Actinic Keratosis (Solar Keratosis)

Field vs Lesional Therapies for AKs 3/2/2019, 9:00-12 AM

Developing the next generation of dermatology products to treat serious skin diseases

A Retrospective Study of Treatment of Squamous Cell Carcinoma In situ. Övermark, Meri.

Benign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc

New Medicines Committee Briefing May 2015

fluorouracil 0.5% / salicylic acid 10% cutaneous solution (Actikerall ) SMC No. (728/11) Almirall S.A.

Large majority caused by sun exposure Often sun exposure before age 20 Persons who burn easily and tan poorly are at greatest risk.

Technicians & Nurses Program

Glenn D. Goldman, MD. Fletcher Allen Health Care. University of Vermont College of Medicine

Scottish Medicines Consortium

Ingenol Mebutate: An Emerging Therapy in the Treatment of Actinic Keratoses

Topical Diclofenac Gel, Fluorouracil Cream, Imiquimod Cream, and Ingenol Gel Prior Authorization with Quantity Limit Program Summary

Periocular Malignancies

Cutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D.

Periocular skin cancer

Identifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018

LUMPS AND BUMPS: AN ORGANIZED APPROACH TO DIAGNOSIS AND MANAGEMENT

Thursday 21 st August Skin Problems

Dermatological Manifestations in the Elderly. Sanjay Siddha Staff Dermatologist UHN & MSH

Ingenol Mebutate: A Succinct Review of a Succinct Therapy

New medicine for actinic keratosis

Actinic keratosis (AK): Dr Sarma s simple guide

AWMSG SECRETARIAT ASSESSMENT REPORT. 5-aminolaevulinic acid (Ameluz ) 78 mg/g gel. Reference number: 1074 FULL SUBMISSION

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Learning Objectives. Tanning. The Skin. Classic Features. Sun Reactive Skin Type Classification. Skin Cancers: Preventing, Screening and Treating

Skin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012

Dermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.

PICATO (ingenol mebutate) gel

Disclosures. I have no conflicts of interest to disclose

BL-5010P A NOVEL PRE-FILLED APPLICATOR FOR THE NON-SURGICAL REMOVAL OF SKIN LESIONS

Clinical Policy: Benign Skin Lesion Removal Reference Number: CP.MP.HN150

Aldara. Aldara (imiquimod) Description

VACAVILLE DERMATOLOGY

Disclosures. Melanoma and Non melanoma Skin Cancer: What You Need to Know. I have no conflicts of interest to disclose

Pre-Cancerous Skin Lesions & Skin Cancer

Corporate Medical Policy

Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects *

Aspects of skin cancer diagnosis in clinical practice

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 26 November 2008

Dual Wavelength Phototherapy System

Eyelid basal cell carcinoma Patient information

Malignant Cutaneous Neoplasms

Clinical Trial Report Synopsis

IT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY

Skin cancer on the scalp pictures

Work Place Carcinogens Solar Radiation and Skin Cancer. November 2013 Dr Mark Foley

Dermatology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI Memorial

Top 10 Skin Problems

Skin Malignancies. Presented by Dr. Douglas Paauw

The future of Skin Cancer Treatment

Clinical Study Report Part 1 of Trial LP

SQUAMOUS CELL CARCINOMA

Clinical Trial Report Synopsis. Efficacy and Safety of LEO in Field Treatment of Actinic Keratosis on Face or Chest including 12-month follow-up

TOPICAL TREATMENT OF ACTINIC KERATOSIS

See spot change: Lesion identification and management in primary care ERIN HENNESSEY DNP, APRN, FNP-C

Skin Cancer. 5 Warning Signs. American Osteopathic College of Occupational and Preventive Medicine OMED 2012, San Diego, Monday, October 8, 2012 C-1

Clinical Study Topical Colchicine Gel versus Diclofenac Sodium Gel for the Treatment of Actinic Keratoses: A Randomized, Double-Blind Study

Have a Voice in Your Choice!

Dermoscopy and Reflectance Confocal Microscopy for Monitoring the Treatment of Actinic Keratosis with Ingenol Mebutate Gel: Report of Two Cases

BSSCII. Skin care after an organ transplant. Patient information. Also for those who have a suppressed immune system

Malignant Cutaneous Neoplasms. Kathleen Haycraft, DNP, FNP/PNP-BC, DCNP, FAANP

Squamous Cell Skin Cancer

Identifying Benign and Malignant Skin Lesions. No Disclosures. Common Benign Lesions. Benign Lesions 2/25/2018. Stucco Keratoses.

Service Specification: CPO Skin Lesions

Dermatology Procedure Coding

Skin Cancer. Dr Elizabeth Ogden Associate Specialist in Dermatology East and North Herts Dr Elizabeth Ogden

Hauora Maori. Map. Non-Melanoma Skin Lesion. Clinically Seborrhoeic Keratosis. Management Options. Punch Biopsy. Refer to Public Skin Lesion Service

Benign and malignant epithelial lesions: Seborrheic keratosis: A common benign pigmented epidermal tumor occur in middle-aged or older persons more

Extreme dermatoheliosis: How to approach the severely sun damaged patient

Minor surgery. Introduction

MOHS MICROGRAPHIC SURGERY: AN OVERVIEW

HEALTH SERVICES POLICY & PROCEDURE MANUAL

Case-Based Approach to Common Dermatologic Neoplasms

NHS. Photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions)

ALL THINGS DERMATOLOGY

Review of Cutaneous Malignancies

Insert to September 2018 A PRACTICAL APPROACH: Field Treatment of AKs with PDT SUPPORTED BY BIOFRONTERA

Keratolytics and Other Topical Dermatological Agents

Oral and Maxillofacial Surgery Department

Skin Cancer - Non-Melanoma

Merkel Cell Carcinoma Case # 2

Malignant non-melanocytic lesions

Transcription:

Old Problems & New Treatments Photo Album by Administrator Richard Turner Consultant Dermatologist

Plan for tonight? Refresher on SCC and solar keratosis How to distinguish the two Classic therapy than can be done in 1 0 care Newer therapies Quiz if we have time!

Solar keratoses Very common in fair skin types Sun exposed sites, scalp and ears in men Diagnosis of palpation and inspection Keratin layer may be pronounced Sometimes painful, pricking sensation Always feel base, if thick or indurated SCC

Bowens disease Lower legs of elderly ladies a Well defined non itchy erythematous plaques and patches, scaly Slow history of growth Don t forget eczema, psoriasis Unresponsive to topical steroids Treat as for solar keratoses

Squamous cell carcinoma Probably overdiagnosed on 2WW Palpation is essential, if thick pain is a worrying sign Keratotic tumours by definition Short history, if really quick and middle aged think keratoacanthoma Don t attempt treatment refer anyway

Quick comparator quiz

Treatment options Cryotherapy 5 fluorouracil (Efudix & Actikerall) Imiquimod (Aldara) Ingenol Mebutate (Picato) Curettage and cautery Excision

Cryotherapy Really useful for benign and premalignant lesions Only appropriate to treat malignancy in secondary care (sbcc and very early SCC) Dosage a bit of an art rather than science Assess the thickness of the lesion and freeze slowly to ensure only the lesion is treated with a narrow margin Keratin an insulator so needs longer freezes

5 Fluorouracil Solar keratoses, Bowens disease & sbcc Differing protocols Our practice bd 2 to 4 weeks on the face Needs to be longer on more distant sites Secondary eczematisation common Impetigo too Counselling essential, don t forget to stop Selfie service

Day 3 Day 5 Day 7 Day 9 Day 10 Day 11 Day 12 Day 14

Day 3 Day 5 Day 7 Day 9 Day 10 Day 12 Day 14 Day 21

Imiquimod Solar keratoses, Bowens disease sbcc, mucosal HPV, lentigo maligna Effective treatment 3X per week for SK, Bowens, LM 5X per week for sbcc Very irritant and can have systemic effects Make a box last!

Ingenol Mebutate Extract of Euphorbia Peplus Petty spurge, radium weed, cancer weed Widespread annual weed Crops up in disturbed ground Used in traditional medicine for years for the treatment of skin cancer

Ingenol Mebutate (Picato) Effective treatment for solar keratoses Faster onset of action cf 5FU Head & neck 3 consecutive days (150mcg/g) Body 2 consecutive days (500 mcg/g) Skin reactions peak within a week or so Red, weeping, crusting and scaling Usually settles within a couple of weeks

Ingenol Mebutate Gel for Actinic Keratosis Mark Lebwohl et al N Engl J Med 2012; 366:1010-1019

Ingenol Mebutate (Picato) Benefits are fewer applications Much more rapid onset Good for patients in work Downsides are inflammation can be profound Pain and occasionally systemic effects Persistent erythema

Mild skin reaction Day 1 Composite LSR Score = 3 Day 57 Composite LSR Score = 1 Day 4 Composite LSR Score = 6 Day 8 Composite LSR Score = 4 Day 15 Composite LSR Score = 2 Day 29 Composite LSR Score = 2 Patient Demographics: 68 years old, Male, Fitzpatrick Type II, Baseline AK Count: 7

Moderate skin reaction Day 1 Composite LSR Score = 0 Day 57 Composite LSR Score = 0 Day 4 Composite LSR Score = 10 Day 8 Composite LSR Score = 8 Day 15 Composite LSR Score = 2 Day 29 Composite LSR Score = 0 Patient Demographics: 53 years old, Male, Fitzpatrick Type II, Baseline AK Count: 7

Moderate skin reactions Day 1 Composite LSR Score = 0 Day 57 Composite LSR Score = 0 Day 3 Composite LSR Score = 12 Day 8 Composite LSR Score = 5 Day 15 Composite LSR Score = 2 Day 29 Composite LSR Score = 1 Patient Demographics: 53 years old, Female, Fitzpatrick Type II, Baseline AK Count: 6

Moderate skin reactions Day 1 Composite LSR Score = 2 Day 57 Composite LSR Score = 1 Day 4 Composite LSR Score = 14 Day 8 Composite LSR Score = 6 Day 15 Composite LSR Score = 1 Day 29 Composite LSR Score = 0 Patient Demographics: 82 years old, Male, Fitzpatrick Type II, Baseline AK Count: 6

Severe skin reactions Day 1 Composite LSR Score = 1 Day 57 Composite LSR Score = 0 Day 4 Composite LSR Score = 21 Day 8 Composite LSR Score = 10 Day 15 Composite LSR Score = 3 Day 29 Composite LSR Score = 0 Patient Demographics: 73 years old, Female, Fitzpatrick Type III, Baseline AK Count: 5

Severe skin reactions Day 1 Composite LSR Score = 1 Day 57 Composite LSR Score = 0 Day 4 Composite LSR Score = 21 Day 8 Composite LSR Score = 10 Day 15 Composite LSR Score = 3 Day 29 Composite LSR Score = 0 Patient Demographics: 73 years old, Female, Fitzpatrick Type III, Baseline AK Count: 5

Shave and cautery

Shave and cautery

Thank you richard.turner@ouh.nhs,uk